Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results

Company Overview - Ardelyx, Inc. (NASDAQ: ARDX) is a biopharmaceutical company focused on developing and commercializing first-in-class gastrointestinal and cardiorenal therapies [3] Financial Updates - TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating, following an update to the firm's financial model ahead of ARDX's fourth-quarter results [1] - Jefferies also raised its price target on Ardelyx, Inc. to $15 from $8 and maintained a Buy rating, highlighting the company as one of the most underrated biotech launches [2] Product and Market Potential - Ardelyx's lead product, tenapanor, treats irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease-related conditions [3] - Peak sales for tenapanor are projected at $1.5–$2 billion by 2035, with additional upside if the new 2041 formulation patent proves defendable [2]